CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Total RadNet, Inc.'s Equity	Common Stock	Common Stock Equity Incentive Plan	Common Stock DeepHealth, Inc.	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2023			67,956,318
Beginning balance at Dec. 31, 2023	$ 813,359	$ 630,695	$ 7			$ 722,750	$ (12,484)	$ (79,578)	$ 182,664
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)			1,299
Issuance of common stock upon exercise of options	8	8				8
Issuance of common stock under the equity compensation plan (in shares)				616,767	4,393
Stock-based compensation expense	11,906	11,906				11,906
Issuance of common stock, net of issuance costs (in shares)			5,232,500
Issuance of common stock, net of issuance costs	218,385	218,385				218,385
Issuance of common stock in connection with acquisitions (in shares)			95,019
Issuance of common stock in connection with acquisitions	4,607	4,607				4,607
Forfeiture of restricted stock and share cancellation (in shares)			(4,642)
Forfeiture of restricted stock and share cancellation	(9)	(9)				(9)
Contributions from noncontrolling interests	11,601	11,601				11,601
Sale of economic interests in majority owned subsidiary, net of taxes	13,517								13,517
Change in cumulative foreign currency translation adjustment	(2,198)	(2,198)					(2,198)
Change in fair value of cash flow hedge from prior periods reclassifed to earnings	739	739					739
Net (loss) income	5,410	(2,779)						(2,779)	8,189
Ending balance (in shares) at Mar. 31, 2024			73,901,654
Ending balance at Mar. 31, 2024	$ 1,077,325	872,955	$ 7			969,248	(13,943)	(82,357)	204,370
Beginning balance (in shares) at Dec. 31, 2024	74,036,993		74,036,993
Beginning balance at Dec. 31, 2024	$ 1,133,410	902,308	$ 7			988,147	(9,061)	(76,785)	231,102
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)	11,956		11,956
Issuance of common stock upon exercise of options	$ 121	121				121
Issuance of common stock under the equity compensation plan (in shares)				906,835	3,438
Stock-based compensation expense	28,514	28,514				28,514
Forfeiture of restricted stock and share cancellation (in shares)			(2,656)
Forfeiture of restricted stock and share cancellation	(20)	(20)				(20)
Distributions paid to noncontrolling interests	913								913
Change in cumulative foreign currency translation adjustment	4,109	4,109					4,109
Change in fair value of cash flow hedge from prior periods reclassifed to earnings	1,033	1,033					1,033
Net (loss) income	$ (29,737)	(37,926)						(37,926)	8,189
Ending balance (in shares) at Mar. 31, 2025	74,956,566		74,956,566
Ending balance at Mar. 31, 2025	$ 1,136,517	$ 898,139	$ 7			$ 1,016,762	$ (3,919)	$ (114,711)	$ 238,378